SecBot SecBot

AGMB

AgomAb Therapeutics NV
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. C9· CIK 0002020932 Biotech & Drug Discovery
$9.05 −0.21 (−2.27%)
Oct 23 4:00 PM ET · prev $9.26
Market cap
$456.0M
Small cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
🔒 Subscribers only
Since first trade
−38.2%
from $14.65 · Feb 6
30 days
−14.5%
from $10.58
Range since listing
$8.23–17.82
−49% from high · low Oct 19
Avg volume 20D
134.4K
Oct 1 spike 639.2K
Short interest
1.00M
≈2.0% of shares · +15.4%
Days to cover
7.1
at average volume
Insider net
+$400.0K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 7 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/9
Strongest BULLISH Agomab Therapeutics dosed the first patient in its Phase 2b NOV-ERA trial of ontunisertib for Fibrostenosing…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $400.0K at an average $8.70. No open-market sales.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +15.4% to 1.00M shares. 7.1 days to cover, ≈2.0% of shares.

  • TrendDOWNTREND

    21% below its 50-day average. New closing low $8.23 on Oct 19.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
HRT FINANCIAL LPTRIM17,075$221.0K
GOLDMAN SACHS GROUP INCTRIM11,800$153.2K
UBS Group AGTRIM2,128$27.6K
MORGAN STANLEYTRIM1,200$15.6K
FEDERATED HERMES, INC.NEW1,618,000$17.0M
FMR LLCNEW1,458,677$15.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy9Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 25, 2026Piper Sandler
INITIATE
INITIATEOverweight
Aug 19, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Jul 23, 2026B. Riley Securities
INITIATE
INITIATEBuy
Jun 22, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$400.0K
bought · 3 insiders
$0
sold · 0 insiders
+4.1%
vs their $8.70 cost
DateInsiderTypeValue
Oct 21, 2026
Epstein David R
Director
BUY$44.5K
Oct 21, 2026
Epstein David R
Director
BUY$44.3K
Oct 8, 2026
Epstein David R
Director
BUY$44.5K
Oct 6, 2026
Epstein David R
Director
BUY$43.5K
Oct 6, 2026
Kemula Pierre Thadee Victor
Chief Financial Officer
BUY$17.1K
Oct 6, 2026
Knotnerus Tim Jasper
Chief Executive Officer
BUY$43.5K
Oct 6, 2026
Kemula Pierre Thadee Victor
Chief Financial Officer
BUY$26.0K
Oct 6, 2026
Kemula Pierre Thadee Victor
Chief Financial Officer
BUY$42.9K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,001,145
shares short
+15.4%
vs prior settlement
7.1
days to cover
≈2.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Director David R. Epstein purchased 10,000 shares of AgomAb Therapeutics for $89K in two open-market trades on October…
INSIDER-BUY — Impact 4/10
Oct 21, 2026 Insider
Epstein David R bought 5,000 shares
Director @ $8.90 ($44.5K)
Oct 21, 2026 Insider
Epstein David R bought 5,000 shares
Director @ $8.86 ($44.3K)
Oct 13, 2026 SEC
Agomab announced the first patient dosed in the global NOV-ERA Phase 2b study of ontunisertib for fibrostenosing…
6-K — Impact 5/10
Oct 13, 2026 Press
Agomab Therapeutics dosed the first patient in its Phase 2b NOV-ERA trial of ontunisertib for Fibrostenosing Crohn's…
Impact 6/10
Oct 13, 2026 FDA
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab announced that the first patient has been dosed in NOV-ERA, the Company's Phase 2b study eval
Oct 8, 2026 Insider
Epstein David R bought 5,000 shares
Director @ $8.90 ($44.5K)
Oct 1, 2026 SEC
Agomab reported positive topline data from the 48-week open-label extension (OLE) of the Phase 2a STENOVA trial for…
6-K — Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 13, 2026
FDA
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab announced that the first patient has been dosed in NOV-ERA, the Company's Phase 2b study evaluating ontunisertib in patients with symptomatic…
Oct 1, 2026
FDA
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab today announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD.
Sep 14, 2026
FDA
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Agomab Therapeutics today announced positive results of the Phase 1 study of AGMB-447 in IPF patients.
Sep 11, 2026
Announcement
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab announced shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders'…
Sep 8, 2026
Trial readout
Results Pending: AGMB-129 (Phase 2) — Completed 80d ago
Trial: STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease Sponsor: Agomab…

SecBot reports

8 filings · 6 press releases · 5 bullish · 0 bearish · 3 neutral
All AGMB filing & press-release reports (14)